Table 1 General characteristics of included studies
Author | Publication year | Country | Target population | Target medication | Intervention type | Duration maximum of the follow-up period (months) | ||
|---|---|---|---|---|---|---|---|---|
Study location | Minimum age (years) | |||||||
Aharaz A. [22] | 2021 | Denmark | Subacute medical outpatient | 18 | PIMs | Medication drug review (pharmacist) | 12 | |
Ashworth N. [23] | 2021 | Canada | Primary care | 65 | BZD | Patient information | 12 | |
Balsom C. [24] | 2020 | Canada | Residents in nursing home | 65 | PIMs | Medication drug review (pharmacist) | 6 | |
Boyé NDA. [25] | 2017 | Netherlands | Hospital, emergency department | 65 | FRID | Medication drug review (research team) | 12 | |
Campbell NL. [26] | 2019 | USA | Hospital, intensive care unit | NA | BZD and anticholinergic | Computerized decision support intervention + pharmacist | 1 | |
Campbell NL. [27] | 2021 | USA | Primary care | 65 | Anticholinergic | Medication drug review (multidisciplinary) | 12 | |
Cateau D. [28] | 2021 | Switzerland | Residents in nursing home | 65 | PIMs | Medication drug review (pharmacist) | 4 | |
Cateau D. [29] | 2021 | Switzerland | Residents in nursing home | NA | PIMs | Medication drug review (pharmacist) | 12 | |
Clyne B. [30] | 2016 | Ireland | Primary care | 70 | PIMs | Medication drug review (multidisciplinary) | 12 | |
Cool C. [31] | 2018 | France | Residents in nursing home | NA | PIMs | Geriatric intervention | 18 | |
Curtin D. [32] | 2020 | Ireland | Residents in nursing home | 75 | PIMs | Medication withdrawal plan communicated to the patient's physician | 3 | |
Dalleur O. [33] | 2014 | Belgium | Hospital, medical ward | 75 | PIMs | Medication drug review (geriatrician) | 12 | |
Edey R. [34] | 2019 | Canada | Hospital, clinical teaching unit | 19 | PIMs | Medication drug review (pharmacist) | 1 | |
Eveleigh R. [35] | 2017 | Netherlands | Primary care | NA | Antidepressant | GP deprescribing (after assessing the appropriateness of the deprescribing attempt) | 12 | |
Gedde MH. [36] | 2021 | Norway | Residents in nursing home | 65 | Psychotropic drugs | Medication drug review (multidisciplinary) | 4 | |
Gnjidic D. [37] | 2019 | Australia | Hospital, medical ward | 65 | BZD | Patient information | 1 | |
Gulla C. [38] | 2018 | Norway | Residents in nursing home | 65 | Antihypertensive drugs | Medication drug review (multidisciplinary) | 9 | |
Hah JM. [39] | 2020 | USA | Hospital, orthopedic surgery unit | 18 | Opioid | Motivational interviewing with patient | 12 | |
Ee C.[40] | 2018 | Singapore | Rehabilitation hospital | NA | Symptomatic medication | Medication drug review (pharmacist) | 1.5 | |
Kersten H. [41] | 2013 | Norway | Residents in nursing home | NA | Anticholinergic | Medication drug review (multidisciplinary) | 4 | |
Kua CH. [42] | 2021 | Singapore | Residents in nursing home | 65 | PIMs | Medication drug review (pharmacist) | 12 | |
Kuntz JL. [43] | 2019 | USA | Primary care | 64 | BZD-related drugs | GP and patient information | 6 | |
Navy HJ. [44] | 2018 | USA | Primary care | 65 | BZD | Patient information | 6 | |
Potter K. [45] | 2016 | Australia | Residents in nursing home | 65 | PIMs | Medication drug review (pharmacist) | 12 | |
Rieckert A. [46] | 2020 | Austria, Italy, United Kingdom | Primary care | 75 | PIMs | Computerized decision support tool providing a comprehensive drug review | 24 | |
Sathienluckana T. [47] | 2018 | Thailand | Outpatient department of psychiatry | 18–50 | Anticholinergic | Pharmacist deprescribing | 3 | |
Smeets CHW. [48] | 2020 | Netherlands | Residents in nursing home | NA | Psychotropic drugs | Medication drug review (multidisciplinary) | 18 | |
Sullivan MD. [49] | 2017 | USA | Primary care | NA | Opioids | Patient information + motivational interviewing with patient | 8.5 | |
Tannenbaum C. [50] | 2014 | Canada | Primary care | 65 | BZD | Patient empowerment intervention | 6 | |
Tseng ES. [51] | 2021 | USA | Hospital, trauma unit | NA | Opioid | Patient information | 1 | |
Van der Meer HG. [52] | 2018 | Netherlands | Primary care | 65 | Anticholinergic and sedative drugs | Medication drug review (pharmacist) | 3 | |
Vicens C. [53] | 2014 | Spain | Primary care | NA | BZD | GP information | 12 | |
Vicens C. [54] | 2016 | Spain | Primary care | NA | BZD | GP information | 36 | |
Wong APY. [55] | 2021 | Singapore | Rehabilitation hospital | 65 | PIMs | Medication drug review (multidisciplinary) | At the discharge | |
Wouters H. [56] | 2017 | Netherlands | Residents in nursing home | NA | PIMs | Medication drug review (multidisciplinary) | 4 | |
Zechmann S. [57] | 2020 | Switzerland | Primary care | 60 | PIMs | Medication drug review (GP) | 12 | |